Comparative Efficacy and Safety of Febuxostat and Allopurinol in Chronic Kidney Disease Stage 3-5 Patients with Asymptomatic Hyperuricemia: a Network Meta-analysis

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2025 Feb 27

PMID 40012480

Authors

Jiaojiao Chen

Yanyun Zhang

Yinglin Wang

Lu Chen

Affiliations

Soon will be listed here.

Abstract

Objective: This study evaluates and compares the effectiveness and safety of febuxostat and allopurinol in chronic kidney disease (CKD) stages 3-5 patients with asymptomatic hyperuricemia using a network meta-analysis.

Methods: A systematic review and network meta-analysis were conducted, adhering to PRISMA-NMA guidelines. Searches included PubMed, Embase, Cochrane Library, and Chinese databases up to June 2024. Randomized controlled trials (RCTs) and cohort studies were assessed for methodological rigor using GRADE.

Results: A total of 12 RCTs and 4 cohort studies ( = 2,423 participants) were included. Febuxostat was associated with greater improvements in estimated glomerular filtration rate compared to allopurinol (MD, 4.99 mL/min/1.73 m; 95%CI -0.65 to 10.78; certainty: low) and placebo (MD, 4.72 mL/min/1.73 m; 95%CI 0.67 to 8.82; low). Serum uric acid reduction was also more pronounced with febuxostat (MD, -0.61 mg/dL; 95%CI -1.15 to -0.05; moderate). Safety outcomes, including major cardiovascular events and adverse events, showed no significant differences between febuxostat and allopurinol. Subgroup analyses revealed enhanced effectiveness of febuxostat at six months of treatment.

Conclusions: This analysis provides robust evidence that febuxostat might offers greater improvements in kidney function and uric acid levels compared to allopurinol or placebo in asymptomatic hyperuricemia with CKD stage 3-5 patients, without compromising safety. These findings can guide clinical decision-making and treatment optimization.

References

Sato Y, Feig D, Stack A, Kang D, Lanaspa M, Ejaz A . The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019; 15(12):767-775. DOI: 10.1038/s41581-019-0174-z. View

Yang X, Zhang B, Cheng Y, Fu S, Jin H . Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2024; 56(1):2332956. PMC: 11095284. DOI: 10.1080/07853890.2024.2332956. View

Rodenbach K, Schneider M, Furth S, Moxey-Mims M, Mitsnefes M, Weaver D . Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study. Am J Kidney Dis. 2015; 66(6):984-92. PMC: 4658318. DOI: 10.1053/j.ajkd.2015.06.015. View

Bardin T, Richette P . Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017; 15(1):123. PMC: 5494879. DOI: 10.1186/s12916-017-0890-9. View

FitzGerald J, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles A . 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020; 72(6):879-895. DOI: 10.1002/art.41247. View

Yang A . Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases . Int J Clin Pharmacol Ther. 2019; 58(1):21-28. DOI: 10.5414/CP203466. View

Sivera F, Andres M, Carmona L, Kydd A, Moi J, Seth R . Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2013; 73(2):328-35. PMC: 3913257. DOI: 10.1136/annrheumdis-2013-203325. View

Badve S, Pascoe E, Tiku A, Boudville N, Brown F, Cass A . Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020; 382(26):2504-2513. DOI: 10.1056/NEJMoa1915833. View

Nata N, Ninwisut N, Inkong P, Supasyndh O, Satirapoj B . Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease. Sci Rep. 2023; 13(1):13494. PMC: 10439119. DOI: 10.1038/s41598-023-40767-5. View

10.

Becker M, Schumacher Jr H, Wortmann R, MacDonald P, Eustace D, Palo W . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450-61. DOI: 10.1056/NEJMoa050373. View

11.

Mackenzie I, Ford I, Nuki G, Hallas J, Hawkey C, Webster J . Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396(10264):1745-1757. DOI: 10.1016/S0140-6736(20)32234-0. View

12.

Sakai Y, Otsuka T, Ohno D, Murasawa T, Sato N, Tsuruoka S . Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease. Ren Fail. 2013; 36(2):225-31. DOI: 10.3109/0886022X.2013.844622. View

13.

Golmohammadi S, Almasi A, Manouchehri M, Omrani H, Zandkarimi M . Allopurinol Against Progression of Chronic Kidney Disease. Iran J Kidney Dis. 2017; 11(4):286-293. View

14.

Saag K, Becker M, Whelton A, Hunt B, Castillo M, Kisfalvi K . Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2018; 71(1):143-153. PMC: 6590450. DOI: 10.1002/art.40685. View

15.

Zhao L, Cao L, Zhao T, Yang X, Zhu X, Zou H . Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis. Chin Med J (Engl). 2020; 133(8):982-993. PMC: 7176444. DOI: 10.1097/CM9.0000000000000682. View

16.

Cha R, Kim S, Bae E, Yu M, Choi B, Choi H . Physicians' perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: A questionnaire survey. Kidney Res Clin Pract. 2019; 38(3):373-381. PMC: 6727886. DOI: 10.23876/j.krcp.19.007. View

17.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

18.

Sapankaew T, Thadanipon K, Ruenroengbun N, Chaiyakittisopon K, Ingsathit A, Numthavaj P . Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials. BMC Nephrol. 2022; 23(1):223. PMC: 9229855. DOI: 10.1186/s12882-022-02850-3. View

19.

Saag K, Whelton A, Becker M, Macdonald P, Hunt B, Gunawardhana L . Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis Rheumatol. 2016; 68(8):2035-43. DOI: 10.1002/art.39654. View

20.

Valsaraj R, Singh A, Gangopadhyay K, Ghoshdastidar B, Goyal G, Batin M . Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes Metab Syndr. 2020; 14(2):93-100. DOI: 10.1016/j.dsx.2020.01.007. View